We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors.
- Authors
Viehweger, Florian; Hoop, Jennifer; Tinger, Lisa-Marie; Bernreuther, Christian; Büscheck, Franziska; Clauditz, Till S.; Hinsch, Andrea; Jacobsen, Frank; Luebke, Andreas M.; Steurer, Stefan; Hube-Magg, Claudia; Kluth, Martina; Marx, Andreas H.; Krech, Till; Lebok, Patrick; Fraune, Christoph; Burandt, Eike; Sauter, Guido; Simon, Ronald; Minner, Sarah
- Abstract
Androgen receptor (AR) is a transcription factor expressed in various normal tissues and is a therapeutic target for prostate and possibly other cancers. A TMA containing 18,234 samples from 141 different tumor types/subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. AR positivity was found in 116 tumor types including 66 tumor types (46.8%) with ≥1 strongly positive tumor. Moderate/strong AR positivity was detected in testicular sex cord-stromal tumors (93.3–100%) and neoplasms of the prostate (79.3–98.7%), breast (25.0–75.5%), other gynecological tumors (0.9–100%), kidney (5.0–44.1%), and urinary bladder (5.4–24.2%). Low AR staining was associated with advanced tumor stage (pTa versus pT2-4; p < 0.0001) in urothelial carcinoma; advanced pT (p < 0.0001), high tumor grade (p < 0.0001), nodal metastasis (p < 0.0001), and reduced survival (p = 0.0024) in invasive breast carcinoma; high pT (p < 0.0001) and grade (p < 0.0001) in clear cell renal cell carcinoma (RCC); and high pT (p = 0.0055) as well as high grade (p < 0.05) in papillary RCC. AR staining was unrelated to histopathological/clinical features in 157 endometrial carcinomas and in 221 ovarian carcinomas. Our data suggest a limited role of AR immunohistochemistry for tumor distinction and a prognostic role in breast and clear cell RCC and highlight tumor entities that might benefit from AR-targeted therapy.
- Subjects
ANDROGEN receptors; TRANSCRIPTION factors; RENAL cell carcinoma; BLADDER; OPTIMISM; LOBULAR carcinoma; BLADDER cancer
- Publication
Biomedicines, 2024, Vol 12, Issue 5, p957
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines12050957